Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Eli Lilly Expands Biotech Incubator Network with New San Diego Site

Eli Lilly Expands Biotech Incubator Network with New San Diego Site

Eli Lilly and Company has officially opened its latest Gateway Labs incubator site in San Diego, marking a significant expansion of its biotech acceleration program. The new facility, located at the One Alexandria Square Megacampus in Torrey Pines, aims to foster collaboration and innovation within the life sciences community.

NoahAI News9/26/2025
Lotus Pharmaceuticals Acquires Alvogen in $2 Billion Deal, Reshaping Generic Drug Landscape

Lotus Pharmaceuticals Acquires Alvogen in $2 Billion Deal, Reshaping Generic Drug Landscape

In a significant move that reshapes the global generic pharmaceutical landscape, Taiwan-based Lotus Pharmaceuticals has acquired a 100% equity stake in Alvogen, valued at up to $2 billion. This strategic acquisition propels Lotus into the ranks of the top 20 specialty pharmaceutical companies worldwide and marks a pivotal moment in the ongoing consolidation of the generics industry.

NoahAI News9/26/2025
US Biotechs Wary of European Licensing Deals Amid Drug Pricing Pressures

US Biotechs Wary of European Licensing Deals Amid Drug Pricing Pressures

US biotechnology companies are increasingly hesitant to license their drugs to European partners, fearing potential backlash from the Trump administration's drug pricing initiatives. This development comes as pharmaceutical firms face mounting pressure on both sides of the Atlantic to address drug pricing disparities and access issues.

NoahAI News9/26/2025
FDA Approves Crinetics' Palsonify, Ushering in New Era for Acromegaly Treatment

FDA Approves Crinetics' Palsonify, Ushering in New Era for Acromegaly Treatment

The U.S. Food and Drug Administration (FDA) has granted approval to Crinetics Pharmaceuticals' Palsonify (paltusotine), marking a significant milestone in the treatment of acromegaly. This oral, once-daily medication represents a paradigm shift in care for patients with the rare pituitary condition, offering a more convenient alternative to current injectable therapies.

NoahAI News9/26/2025
Eli Lilly's Inluriyo Secures FDA Approval for Advanced Breast Cancer Treatment

Eli Lilly's Inluriyo Secures FDA Approval for Advanced Breast Cancer Treatment

Eli Lilly has achieved a significant milestone in the pharmaceutical industry with the U.S. Food and Drug Administration's (FDA) approval of Inluriyo (imlunestrant) for the treatment of advanced breast cancer. This development marks a crucial advancement in oral selective estrogen receptor degrader (SERD) therapies and offers new hope for patients with specific genetic mutations.

NoahAI News9/26/2025
Heartflow Advances Coronary Plaque Analysis with FDA Clearance and Expanded Insurance Coverage

Heartflow Advances Coronary Plaque Analysis with FDA Clearance and Expanded Insurance Coverage

Heartflow, a leader in cardiovascular diagnostics, has made significant strides in coronary plaque analysis technology, securing FDA clearance for an updated algorithm and gaining coverage from major insurers. These developments mark a pivotal moment in the company's growth and the broader field of cardiac imaging.

NoahAI News9/26/2025
Pennsylvania Life Sciences Job Market Shows Resilience Amid Industry Challenges

Pennsylvania Life Sciences Job Market Shows Resilience Amid Industry Challenges

The pharmaceutical and biotechnology job market in Pennsylvania continues to offer opportunities for life sciences professionals, despite a notable decline in overall job postings. Recent data reveals a complex landscape where established companies maintain hiring momentum, even as the broader industry faces headwinds.

NoahAI News9/26/2025
Guardant Health Expands Cancer Detection Portfolio with Multi-Cancer Test and Quest Partnership

Guardant Health Expands Cancer Detection Portfolio with Multi-Cancer Test and Quest Partnership

Guardant Health, a leader in precision oncology, has announced significant developments in its cancer detection portfolio, including a new multi-cancer detection test and a strategic partnership with Quest Diagnostics. These moves are set to reshape the landscape of early cancer screening and expand access to innovative diagnostic tools.

NoahAI News9/26/2025
Immuneering's Atebimetinib Shows Promise in Pancreatic Cancer Treatment

Immuneering's Atebimetinib Shows Promise in Pancreatic Cancer Treatment

Immuneering Corporation has reported encouraging results from a mid-stage clinical trial of its investigational drug atebimetinib in pancreatic cancer patients. The study, which combined atebimetinib with standard chemotherapies, demonstrated significant improvements in overall survival and progression-free survival compared to current treatment standards.

NoahAI News9/26/2025
Lilly Halts Obesity Trial, Raising Questions About Muscle-Sparing Drugs

Lilly Halts Obesity Trial, Raising Questions About Muscle-Sparing Drugs

Eli Lilly has terminated a mid-stage clinical trial evaluating bimagrumab, a muscle-sparing antibody, in combination with its blockbuster weight-loss drug Zepbound (tirzepatide). The decision, attributed to "strategic business reasons," comes amid growing interest in therapies designed to preserve muscle mass during weight loss treatment.

NoahAI News9/26/2025
Major Players Implement Substantial Workforce Reductions

Major Players Implement Substantial Workforce Reductions

Several industry giants have announced significant job cuts in recent months. Novartis is reducing its U.S. workforce by 427 employees at its East Hanover, New Jersey headquarters, with layoffs scheduled from June to October 2025. This follows the company's December 2024 decision to let go of 330 employees as part of site closures in Germany and Boston.

NoahAI News9/26/2025
Harmony's Fragile X Syndrome Trial Failure Raises Questions About ZYN002's Future

Harmony's Fragile X Syndrome Trial Failure Raises Questions About ZYN002's Future

Harmony Biosciences faced a significant setback as its pivotal Phase III RECONNECT trial for the synthetic cannabidiol candidate ZYN002 failed to meet its primary efficacy endpoint in treating fragile X syndrome. The company attributed the disappointing results to a higher-than-expected placebo response rate, casting doubt on the future of the drug and its development program.

NoahAI News9/26/2025
«1...616263...67»